This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Looking at Updated NMIBC data from Protara's TARA-002 and Relmanda Therapeutics NDV-01
Ticker(s): TARA, RLMDWho's the expert?
NYU Langone Health
- Urologic Oncologist, Professor and Vice Chair of Clinical Affairs at NYU Grossman School of Medicineand Chief of Urology at Tisch Hospital
- Treats 200+ cancer patients surgically per year across kidney, bladder, prostate, and other urologic cancers.
- Specializes in caring for adults with kidney cancer, bladder cancer, prostate cancer, testicular cancer, and other genitourinary malignancies; his research focuses on translational approaches to improve surgical outcomes and quality of life for kidney cancer patients, and novel strategies for bladder and other urologic cancers, including involvement in clinical trials and new treatment modalities.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
